• KOL
    • Arthritis
    • Arthritis Kols
    • Maxime R DOUGADOS

      Maxime R DOUGADOS

      Hopital Cochin, Rheumatology, University of Paris, Paris, France | Université de Paris, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris ...



      KOL Resume for Maxime R DOUGADOS


      Hopital Cochin, Rheumatology, University of Paris, Paris, France


      Department of Rheumatology, Université de Paris, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France

      for the CORIMUNO-19 Collaborative Group

      Paris-Descartes University; UPRES-EA 4058; Cochin Hospital.


      Department of Rheumatology - Hôpital Cochin. Assistance Publique, Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité, Université de Paris, Paris, France

      Rhumatologie b, Hôpital Cochin, Paris



      Maxime R DOUGADOS: Influence Statistics

      Sample of concepts for which Maxime R DOUGADOS is among the top experts in the world.
      Concept World rank
      7675 #1
      dougados #1
      nurse icc #1
      osteoporosis mscq #1
      psoriasis presence #1
      primary inefficacy tnfi #1
      asdascrp basdai #1
      spirochaetal aetiology #1
      rays vfa #1
      gdp higher das28 #1
      jsw tha #1
      tender joints 95 #1
      fatigue text #1
      asasic expert panel #1
      articulaire #1
      work impairment patients #1
      remission 6 criteria #1
      actray study #1
      spondylarthropathy study #1
      3 registries #1
      hyalgan #1
      chondroscopy #1
      arthritis rheum #1
      tolerability joint lavage #1
      selfreported ability #1
      circulating concentration infliximab #1
      axiale #1
      axspa based #1
      synovitis 95 #1
      tczmtx tczpbo #1
      medicoeconomics #1
      patients central reading #1
      video preoperative anxiety #1
      paracetamol knee #1
      160 patients 95 #1
      remission radiographic progression #1
      criteria amor #1
      uveitis spa #1
      baseline nsaids #1
      embark study #1
      pspa criteria #1
      tnfi recommendation #1
      pass estimates #1
      recommandée #1
      extended views #1
      axspa daily practice #1
      224weeks #1
      multidisciplinary consultation #1
      peripheral manifestations patients #1
      asdas 09 points #1


      Prominent publications by Maxime R DOUGADOS

      KOL-Index: 22533

      PURPOSE: As a prelude to developing updated, evidence-based, international consensus recommendations for the management of hip and knee osteoarthritis (OA), the Osteoarthritis Research Society International (OARSI) Treatment Guidelines Committee undertook a critical appraisal of published guidelines and a systematic review (SR) of more recent evidence for relevant therapies.

      METHODS: Sixteen experts from four medical disciplines (primary care two, rheumatology 11, orthopaedics one and ...

      Known for Critical Appraisal | Knee Osteoarthritis | Treatment Guidelines | Oarsi Recommendations | Management Hip
      KOL-Index: 21135

      Importance: Severe pneumonia with hyperinflammation and elevated interleukin-6 is a common presentation of coronavirus disease 2019 (COVID-19).

      Objective: To determine whether tocilizumab (TCZ) improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia.

      Design, Setting, and Particpants: This cohort-embedded, investigator-initiated, multicenter, open-label, bayesian randomized clinical trial investigating patients with COVID-19 and moderate or severe pneumonia ...

      Known for Patients Tcz | Severe Pneumonia | Day Uc | Noninvasive Ventilation | Intensive Unit
      KOL-Index: 19826

      OBJECTIVE: To determine the efficacy and safety of treatment with rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapies and to explore the pharmacokinetics and pharmacodynamics of rituximab in this population.

      METHODS: We evaluated primary efficacy and safety at 24 weeks in patients enrolled in the Randomized Evaluation of Long-Term Efficacy of Rituximab in RA (REFLEX) Trial, a ...

      Known for 24 Weeks | Primary Efficacy | Rituximab Monoclonal Antibodies | Rheumatoid Arthritis Refractory | Tumor Necrosis
      KOL-Index: 19690

      PURPOSE: To develop concise, patient-focussed, up to date, evidence-based, expert consensus recommendations for the management of hip and knee osteoarthritis (OA), which are adaptable and designed to assist physicians and allied health care professionals in general and specialist practise throughout the world.

      METHODS: Sixteen experts from four medical disciplines (primary care, rheumatology, orthopaedics and evidence-based medicine), two continents and six countries (USA, UK, France, ...

      Known for Consensus Guidelines | Knee Osteoarthritis | Management Hip | Based Evidence | Chondroitin Sulphate
      KOL-Index: 18299

      OBJECTIVE: To validate and compare the definition of the Disease Activity Score 28 based on C-reactive protein (DAS28 (CRP)) to the definition based on erythrocyte sedimentation rate (ESR).

      METHODS: Data were analysed from two randomised, double-blind, placebo-controlled trials of abatacept of 6-month and 12-month duration in patients with rheumatoid arthritis. European League Against Rheumatism (EULAR) response criteria and the proportion of patients in remission (DAS28 <2.6) based on ...

      Known for European League | Rheumatoid Arthritis | Erythrocyte Sedimentation Rate | Response Criteria | Das28 Based
      KOL-Index: 18225

      OBJECTIVES: To evaluate the efficacy and safety of certolizumab pegol (CZP) after 24 weeks in RAPID-axSpA (NCT01087762), an ongoing Phase 3 trial in patients with axial spondyloarthritis (axSpA), including patients with ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).

      METHODS: Patients with active axSpA were randomised 1:1:1 to placebo, CZP 200 mg every 2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W). In total 325 patients were randomised. Primary endpoint was ASAS20 ...

      Known for Ankylosing Spondylitis | Certolizumab Pegol | Placebo Czp | Axspa Patients | Improvements Week
      KOL-Index: 17791

      BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis.

      METHODS: In two double-blind trials, we randomly assigned patients to receive secukinumab or placebo. In MEASURE 1, a total of 371 patients received intravenous secukinumab (10 mg per kilogram of body weight) or matched placebo at weeks ...

      Known for Ankylosing Spondylitis | Secukinumab Patients | 150 75 | Week Measure | Monoclonal Antibodies
      KOL-Index: 17635

      OBJECTIVE: The hallmark of osteoarthritis (OA) is the loss of articular cartilage. This loss arises from an imbalance between cartilage synthesis and cartilage degradation over a variable period of time. The aims of this study were to investigate the rates of these processes in patients with knee OA using two new molecular markers and to investigate whether the combined use of these markers could predict the progression of joint damage evaluated by both radiography and arthroscopy of the ...

      Known for Joint Damage | Patients Knee | Collagen Synthesis | 1 Year | Serum Levels Piianp
      KOL-Index: 17006

      OBJECTIVE: To compare work disability, sick leave, and productivity costs due to ankylosing spondylitis (AS) of three European countries.

      METHODS: 216 patients with AS from the Netherlands, France, and Belgium participated in a two year observational study. Employment and work disability rates at baseline were adjusted for age and sex. Productivity costs were calculated by both the friction cost method and the human capital approach. The adjusted contributions of country to employment, ...

      Known for Productivity Costs | European Countries | Work Status | Sick Leave | Ankylosing Spondylitis
      KOL-Index: 16755

      OBJECTIVES: This double-blind trial evaluated the efficacy and safety of abatacept or infliximab vs placebo. The primary objective of this study was to evaluate the mean change from baseline in Disease Activity Score (based on erythrocyte sedimentation rates; DAS28 (ESR)) for the abatacept vs placebo groups at day 197.

      METHODS: Patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX) were randomised 3:3:2 to abatacept ( approximately 10 mg/kg every 4 ...

      Known for Rheumatoid Arthritis | Inadequate Response | Efficacy Abatacept | Aes Infliximab | Safety Treatment
      KOL-Index: 16607

      PURPOSE: To evaluate the efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

      METHODS: Patients fulfilled Assessment of Spondyloarthritis international Society (ASAS) criteria for axial spondyloarthritis, had a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥ 4, total back pain score of ≥ 4 (10 cm visual analogue scale) and inadequate response, intolerance or contraindication to non-steroidal anti-inflammatory drugs ...

      Known for Patients Adalimumab | Efficacy Safety | Radiographic Axial | Inadequate Response | Asdas Basdai
      KOL-Index: 16452

      OBJECTIVES: To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial spondyloarthritis (r-axSpA) who were biological disease-modifying antirheumatic drug (bDMARD)-naive (COAST-V) or tumour necrosis factor inhibitor (TNFi)-experienced (COAST-W).

      METHODS: Adults with active r-axSpA were randomised 1:1:1:1 (n=341) to 80 mg ixekizumab every 2 (IXE Q2W) or 4 weeks (IXE Q4W), placebo (PBO) or 40 mg adalimumab Q2W ...

      Known for 52 Weeks | Pbo Ixe | Efficacy Safety | Week Patients | Radiographic Axial
      KOL-Index: 16140

      OBJECTIVE: Remission in rheumatoid arthritis (RA) is an increasingly attainable goal, but there is no widely used definition of remission that is stringent but achievable and could be applied uniformly as an outcome measure in clinical trials. This work was undertaken to develop such a definition.

      METHODS: A committee consisting of members of the American College of Rheumatology, the European League Against Rheumatism, and the Outcome Measures in Rheumatology Initiative met to guide the ...

      Known for Rheumatoid Arthritis | European League | Definition Remission | Outcome Measure | Illness Terminology
      KOL-Index: 16043

      BACKGROUND: Biological disease-modifying anti-rheumatic drugs (bDMARDs) are recommended for radiographic axial spondyloarthritis, otherwise known as ankylosing spondylitis, when conventional therapies are not effective. We report efficacy and safety data on ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A (IL-17A), in patients with radiographic axial spondyloarthritis who have not previously been treated with bDMARDs.

      METHODS: In this phase 3, ...

      Known for Radiographic Axial | Ixekizumab Q4w | Rheumatic Drugs | Phase 3 | Biological Disease
      KOL-Index: 15685

      OBJECTIVES: To compare retention rates of adalimumab, etanercept and infliximab as first-line biotherapy in rheumatoid arthritis (RA), to determine causes of discontinuation, retention-associated factors, and retention rates of possible second-line TNF-α inhibitors (TNFi).

      METHODS: In this retrolective, multicentric study, medical charts of RA patients starting TNFi between March 2005 and April 2009 were reviewed, with follow-up between two and six years. The retention rate was estimated ...

      Known for Retention Rates | Adalimumab Etanercept | Rheumatoid Arthritis | Monoclonal Antibodies | Daily Practice

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Maxime R DOUGADOS:Expert Impact

      Concepts for whichMaxime R DOUGADOShas direct influence:Rheumatoid arthritis,  Ankylosing spondylitis,  Axial spondyloarthritis,  Desir cohort,  Psoriatic arthritis,  Hip osteoarthritis,  Patients rheumatoid arthritis,  Radiographic progression.

      Maxime R DOUGADOS:KOL impact

      Concepts related to the work of other authors for whichfor which Maxime R DOUGADOS has influence:Rheumatoid arthritis,  Ankylosing spondylitis,  Rheumatic diseases,  Knee pain,  Systemic lupus erythematosus,  Necrosis factor,  Radiographic progression.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Hopital Cochin, Rheumatology, University of Paris, Paris, France | Université de Paris, Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.